Treatment News : Gilead Begins Phase III Studies of Low-Dose Prodrug Tenofovir Alafenamide

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » January 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


January 28, 2013

Gilead Begins Phase III Studies of Low-Dose Prodrug Tenofovir Alafenamide

Following encouraging Phase II data announced in the fall, Gilead Sciences has begun two Phase III clinical trials of a single-tablet, once-a-day antiretroviral regimen containing tenofovir alafenamide fumarate (TAF) among treatment-naive adults.  TAF is a prodrug formulation of the active agent in Viread (tenofovir disoproxil fumarate, TDF). Prodrugs are medications that are inactive until metabolized by the body, a process that allows for lower dosing.  

Both of the new trials are randomized and double-blind and will be conducted for 96 weeks among HIV-positive participants with viral loads greater than 1,000 at the outset.  Half of the 840 people in each study will be randomized between receiving a once-a-day tablet of TAF/elvitegravir/cobicistat/emtricitabine or Gilead’s Stribild (elvitegravir/cobicistat/emtricitabine/TDF), which was approved by the U.S. Food and Drug Administration in 2012.  The study’s primary endpoint will be the proportion of participants who reach an undetectable viral load after 48 weeks of treatment. After the Phase II results showed the TAF-based combination therapy showed improved kidney and bone safety, the study will include patients with impaired kidney function and will assess bone mineral density of all participants.

“We believe that TAF’s smaller milligram size has the potential to offer safety and tolerability advantages over existing therapies, and may enable the creation of new single tablet regimens for HIV,” said Norbert Bischofberger, PhD, executive vice president of research and development and chief scientific officer at Gilead.

To read the Gilead release, click here.

Search: Gilead, HIV, Phase III, low-dose prodrug, tenofovir alafenamide fumarate, TAF, Viread, tenofovir disoproxil fumarate, TDF, Stribild, elvitegravir, cobicistat, emtricitabine, viral load, kidney, bone, Norbert Bischofberger.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.